Home
/
Karyopharm Therapeutics Inc.
/
Financials
/
Quarterly
Karyopharm Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Karyopharm Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$44.04M
Nov 3, 2025
Q2
2025
Jun 30, 2025
$37.93M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$30.02M
May 12, 2025
Q3
2025
Sep 30, 2024
$38.78M
Nov 3, 2025
Q2
2025
Jun 30, 2024
$42.79M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$33.13M
May 12, 2025
Q3
2024
Sep 30, 2023
$36.01M
Nov 5, 2024
Q2
2024
Jun 30, 2023
$37.58M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$38.70M
May 8, 2024
Q3
2023
Sep 30, 2022
$36.15M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$39.68M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$47.67M
May 4, 2023
Q3
2022
Sep 30, 2021
$37.69M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$22.60M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$23.26M
May 5, 2022
Q3
2021
Sep 30, 2020
$21.33M
Nov 3, 2021
Q2
2021
Jun 30, 2020
$33.51M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$18.14M
May 4, 2021
Q3
2020
Sep 30, 2019
$13.15M
Nov 2, 2020
Q2
2020
Jun 30, 2019
$9.49M
Aug 4, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2017
Mar 31, 2017
$68.0K
May 4, 2017
Q3
2016
Sep 30, 2016
$48.0K
Nov 7, 2016
Q2
2016
Jun 30, 2016
$59.0K
Aug 4, 2016
Q3
2016
Sep 30, 2015
$75.0K
Nov 7, 2016
Q2
2016
Jun 30, 2015
$150.0K
Aug 4, 2016
Q3
2015
Sep 30, 2014
$21.0K
Nov 9, 2015
Q2
2015
Jun 30, 2014
$21.0K
Aug 10, 2015
Q1
2015
Mar 31, 2014
$171.0K
May 11, 2015
Q3
2014
Sep 30, 2013
$366.0K
Nov 10, 2014
Q2
2014
Jun 30, 2013
$133.0K
Aug 7, 2014
Q1
2014
Mar 31, 2013
$233.0K
May 8, 2014
Q3
2013
Sep 30, 2012
$34.0K
Dec 23, 2013
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($33.13M)
Nov 3, 2025
Q2
2025
Jun 30, 2025
($37.25M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($23.46M)
May 12, 2025
Q3
2025
Sep 30, 2024
($32.07M)
Nov 3, 2025
Q2
2025
Jun 30, 2024
$23.79M
Aug 11, 2025
Q1
2025
Mar 31, 2024
($37.36M)
May 12, 2025
Q3
2024
Sep 30, 2023
($34.51M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($32.63M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($34.13M)
May 8, 2024
Q3
2023
Sep 30, 2022
($36.32M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($49.06M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($41.40M)
May 4, 2023
Q3
2022
Sep 30, 2021
($51.81M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($53.58M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($57.41M)
May 5, 2022
Q3
2021
Sep 30, 2020
($53.50M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($46.43M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($52.93M)
May 4, 2021
Q3
2020
Sep 30, 2019
($41.37M)
Nov 2, 2020
Q2
2020
Jun 30, 2019
($43.42M)
Aug 4, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($15.22M)
Nov 3, 2025
Q2
2025
Jun 30, 2025
($24.39M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($33.26M)
May 12, 2025
Q3
2025
Sep 30, 2024
($26.28M)
Nov 3, 2025
Q2
2025
Jun 30, 2024
($28.12M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($33.76M)
May 12, 2025
Q3
2024
Sep 30, 2023
($31.26M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($29.57M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($30.90M)
May 8, 2024
Q3
2023
Sep 30, 2022
($30.84M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($42.91M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($34.59M)
May 4, 2023
Q3
2022
Sep 30, 2021
($43.81M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($49.05M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($52.37M)
May 5, 2022
Q3
2021
Sep 30, 2020
($47.11M)
Nov 3, 2021
Q2
2021
Jun 30, 2020
($40.32M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($47.36M)
May 4, 2021
Q3
2020
Sep 30, 2019
($39.40M)
Nov 2, 2020
Q2
2020
Jun 30, 2019
($41.69M)
Aug 4, 2020